| |
|
|
|
|
|
 |
| |
|
리바트라연고 RIBATRA OINTMENT[Bacitracin , Ribavirin]
|
|
일반의약품 | 삭제
|
|
|
| |
 |
알림: |
드럭인포에서는 의약품 인터넷 판매를 하지 않습니다. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
유료회원 결재시에는 보다 다양한 약물정보를
이용하실 수 있습니다.
유료정보목록은 전문회원으로
로그인 하시면 확인 가능합니다.
|
|
|
 | 허가정보 |
|
|
|
|
| 정보요약 |
|
|
|
드럭인포 의약품 요약/상세정보
|
|
| 코드 및 분류정보 |
|
|
| 항목 |
내용 |
| 대표코드 |
8806485054307 |
| BIT 약효분류 |
외용 항바이러스제 (Antivirals : Skin & Mucous Membrane)
|
| ATC 코드 |
Antivirals / D06BB
[코드분류상세설명]
[ATC코드예측]
|
| 복지부분류코드 |
269 (기타의 외피용약 )
|
| 의약품 바코드정보 |
내용보기
8806103878247//튜브//1 단위/수량: 1
8806103878339//튜브//1 단위/수량: 1
8806103851363//튜브//20 단위/수량: 20
|
주성분코드 분석 및
중복처방 검토 |
[주성분코드 분석 및 중복처방 검토]
|
| Drugs By Indication |
[전체보기]
|
| Drugs By Classification |
[전체보기]
|
|
|
| 제품정보 |
|
|
| 항목 |
내용 |
청구코드(KD코드)
비급여점검코드
상한금액 |
648505430[A00302701]
[보험코드에 따른 약품기본정보 직접조회]
\0 원/1g(2007.12.01)(최신약가)
\286 원/1g(2007.01.01)(변경전약가)
[상병코드조회]
[질병코드집 다운로드]
|
| 제품성상 |
백색~엷은 황색의 연고제
[제형정보 확인]
|
| 포장·유통단위 |
5G |
| Brandname 정보 |
Ribavirin
Brand Names/Synonyms
- Biopolymers
- Copegus
- RBV
- RIBAV
- RTC
- RTCA
- RTP
- Rebetol
- Rebetron
- Rebretron
- Ribamide
- Ribamidil
- Ribamidyl
- Ribasphere
- Ribavirin Capsules
- Ribavirin Triphosphate
- Ribavirin [Usan:Inn]
- Ribavirin-TP
- Ribavirina [Inn-Spanish]
- Ribavirine
- Ribavirine [Inn-French]
- Ribavirinum [Inn-Latin]
- Tribavirin
- Varazid
- Vilona
- Viramid
- Virazid
- Virazole
- Virazole 5'-triphosphate
Brand Name MixturesRebetron (Ribavirin + Interferon alpha)
Chemical IUPAC Name1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamideBacitracin
Brand Names/Synonyms
- Baci-rx
- Baciguent
- Baciim
- Bacitracin Bacillus licheniformis
- Ziba-rx
Brand Name Mixtures
- Antibiotic Ointment (Bacitracin + Polymyxin B (Polymyxin B Sulfate))
- Aurex Rotenone Drops (Bacitracin + Penicillin + Rotenone + Streptomycin (Streptomycin Sulfate) + Undecylenic Acid)
- Baciguent Plus Pain Reliever Ont (Bacitracin + Lidocaine)
- Bacitracin-Neomycin Polymyxin Ont (Bacitracin Zinc + Neomycin Sulfate + Polymyxin B Sulfate)
- Bacitracin-Neomycin-Polymixin Ont (Bacitracin Zinc + Neomycin Sulfate + Polymyxin B Sulfate)
- Bacitracin-Neomycin-Polymyxin Oph Ont (Bacitracin Zinc + Neomycin Sulfate + Polymyxin B Sulfate)
- Band-Aid-S-1 (Bacitracin Zinc + Polymyxin B Sulfate)
- Cortisporin (Bacitracin (Bacitracin Zinc) + Hydrocortisone + Neomycin (Neomycin Sulfate) + Polymyxin B (Polymyxin B Sulfate))
- Cortisporin (Bacitracin Zinc + Hydrocortisone + Neomycin Sulfate + Polymyxin B Sulfate)
- Emercreme No4 Ont Efa (Bacitracin + Benzocaine + Cetylpyridinium Chloride + Diphenylpyraline Hydrochloride + Tyrothricin)
- First Aid Antibiotic (Bacitracin Zinc + Polymyxin B Sulfate)
- First Aid Antibiotic Ointment (Bacitracin Zinc + Polymyxin B Sulfate)
- Gercillin (Bacitracin + Benzocaine + Polymyxin B Sulfate + Tyrothricin)
- Lanabiotic Ont (Bacitracin + Polymyxin B Sulfate)
- Mycitracin Oph Ont (Bacitracin + Neomycin Sulfate + Polymyxin B Sulfate)
- Neo Bace Ophthalmic Ointment (Bacitracin + Polymyxin B Sulfate)
- Neosporin Ointment (Bacitracin (Bacitracin Zinc) + Neomycin (Neomycin Sulfate) + Polymyxin B (Polymyxin B Sulfate))
- Neosporin Ophthalmic Ointment (Bacitracin (Bacitracin Zinc) + Neomycin (Neomycin Sulfate) + Polymyxin B (Polymyxin B Sulfate))
- Neotopic Ointment (Bacitracin (Bacitracin Zinc) + Neomycin (Neomycin Sulfate) + Polymyxin B (Polymyxin B Sulfate))
- Ozonol Antibiotic Plus - Ointment (Bacitracin + Lidocaine Hydrochloride + Polymyxin B (Polymyxin B Sulfate))
- Ozonol Antibiotic Plus Ont (Bacitracin + Lidocaine Hydrochloride + Polymyxin B Sulfate)
- Polycidin Ophthalmic Ointment (Bacitracin (Bacitracin Zinc) + Polymyxin B (Polymyxin B Sulfate))
- Polyderm Antibiotic Ointment (Bacitracin + Lidocaine Hydrochloride + Polymyxin B Sulfate)
- Polysporin Antibiotic Ointment (Bacitracin + Polymyxin B (Polymyxin B Sulfate))
- Polysporin Sterile Ophthalmic Ointment (Bacitracin (Bacitracin Zinc) + Polymyxin B (Polymyxin B Sulfate))
- Polysporin Topical First Aid Antibiotic Ointment (Bacitracin + Polymyxin B (Polymyxin B Sulfate))
- Polysporin Triple Antibiotic Ointment (Bacitracin + Gramicidin + Polymyxin B (Polymyxin B Sulfate))
- Polytopic Ont (Bacitracin + Polymyxin B (Polymyxin B Sulfate))
- Polytracin Ont (Bacitracin Zinc + Polymyxin B (Polymyxin B Sulfate))
- Sandoz Cortimyxin (Bacitracin (Bacitracin Zinc) + Hydrocortisone + Neomycin (Neomycin Sulfate) + Polymyxin B (Polymyxin B Sulfate))
Chemical IUPAC Name4-[2-[[2-(1-amino-2-methyl-butyl)-4,5-dihydro-1,3-thiazol-5-yl]carbonylamino]-4-methyl-
pentanoyl]amino-5-[1-[[18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-3-(carbamoylmethyl)
-6-(carboxymethyl)-9-(3H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,
13,16,19-heptazacyclopentacos-21-yl]carbamoyl]-2-methyl-butyl]amino-5-oxo-pentanoic
acid
|
|
|
| 복약정보 |
|
|
| 항목 |
내용 |
| LACTmed 바로가기 |
[바로가기]
|
| 약리작용 |
유료정보입니다.
|
| 복약지도 |
유료정보입니다.
|
| 임부에대한투여 |
| * |
전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.
|
|
| |
FDA : X등급
(ribavirin; )
|
|
| * |
상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
|
| * |
반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.
|
|
|
| Pharmacokinetics |
유료정보입니다.
|
| 병용금기 및 연령대금기 근거조회 |
[병용금기 및 연령대금기 근거조회]
|
| 제형별 복약지도 |
[연고] |
| 보관상 주의 |
|
| 조제시 주의 |
|
|
|
| 심사정보 |
|
|
|
|
| 학술정보 |
|
|
| 항목 |
내용 |
| DUR (의약품사용평가) |
병용금기 :
고시된 병용금기 내용은 없습니다.
[상호작용/병용금기검색]
연령대금기 :
고시된 연령금기 내용은 없습니다.
[연령대금기상세검색]
|
| 독성정보 |
Bacitracin에 대한 독성정보 : 정보보기
출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Bacitracin에 대한 Mechanism_Of_Action 정보
Bacitracin intereferes with the dephosphorylation of the 55-carbon, biphosphate lipid transport molecule, which carries the building blocks of the peptidoglycan bacterial cell wall outside the inner membrane for construction.
Ribavirin에 대한 Mechanism_Of_Action 정보
Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral). Guanylyltranserase inhibition stops the capping of mRNA. These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.
|
| Pharmacology |
Bacitracin에 대한 Pharmacology 정보
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. As a polypeptide, toxic, and difficult to use chemical, Bacitracin doesn't work well orally, however is very effective topically. Bacitracin exerts pronounced antibacterial action in vitro against a variety of gram-positive and a few gram-negative organisms. However, among systemic diseases, only staphylococcal infections qualify for consideration of bacitracin therapy.
Ribavirin에 대한 Pharmacology 정보
Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease.
|
| Metabolism |
Bacitracin에 대한 Metabolism 정보
# Phase_1_Metabolizing_Enzyme:Not Available
Ribavirin에 대한 Metabolism 정보
# Phase_1_Metabolizing_Enzyme:Adenosine kinase
|
| Protein Binding |
Bacitracin에 대한 단백결합 정보
Not Available
Ribavirin에 대한 단백결합 정보
Not Available
|
| Half-life |
Bacitracin에 대한 반감기 정보
Not Available
Ribavirin에 대한 반감기 정보
9.5 hours
|
| Absorption |
Bacitracin에 대한 Absorption 정보
Absorption of bacitracin following intramuscular injection is rapid and complete. Absorption from the gastrointestinal tract following oral administration is not appreciable. Absorption following topical application is negligible.
Ribavirin에 대한 Absorption 정보
Rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averages 64%.
|
| Pharmacokinetics |
Bacitracin의 약물동력학자료
- 작용지속시간 : 6-8시간
- 흡수 :
- 외용 : 점막, 정상 피부, 손상된 피부로부터 거의 흡수되지 않는다.
- IM : 빠르게 흡수된다.
- 방광 관주 : 거의 흡수되지 않는다.
- 복막 세척, 종격동 세척 : 흡수된다.
- 분포 : 뇌수막염시에도 뇌척수액으로의 분포는 미미하다.
- 단백결합 : 혈중 단백에 거의 결합하지 않는다.
- 혈중최고농도 도달시간 : IM : 1-2시간
- 소실 : 24시간 이내에 10-40%가 천천히 신배설
Ribavirin의 약물동력학자료
- 흡수 : 비강 또는 경구 흡입시 호흡기를 통해 전신으로 흡수된다.
- 흡수되는 양은 호흡인자 (respiratory factors)와 약물수송 방법에 따라 다르다.
- 기관지 삽관 후 에어로졸 제제를 사용할 때 최대로 흡수된다.
- 분포 : 기관지, 적혈구에 가장 높은 농도로 분포한다.
- 대사 : 세포내에서 대사되어 활성화된다.
- 반감기 : 혈중 :
- 최고혈중농도 도달시간 : 흡입 : 60-90 분
- 소실 : 주 소실 경로는 간대사이며, 40% 정도가 미변화체 및 대사체로 신배설된다.
|
| Biotransformation |
Bacitracin에 대한 Biotransformation 정보
Not Available
Ribavirin에 대한 Biotransformation 정보
Hepatic. Results of in vitro studies using both human and rat liver microsome preparations indicated little or no cytochrome P450 enzyme-mediated metabolism of ribavirin, with minimal potential for P450 enzyme-based drug interactions. Ribavirin has two pathways of metabolism: (1) a reversible phosphorylation pathway in nucleated cells; and (2) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite.
|
| Toxicity |
Bacitracin에 대한 Toxicity 정보
Oral, mouse: LD50 = >3750 mg/kg.
Ribavirin에 대한 Toxicity 정보
Side effects include "flu-like" symptoms, such as headache, fatigue, myalgia, and fever. The LD50 in mice is 2 g/kg orally and is associated with hypoactivity and gastrointestinal symptoms (estimated human equivalent dose of 0.17 g/kg, based on body surface area conversion).
|
| Drug Interactions |
Bacitracin에 대한 Drug_Interactions 정보
Not Available
Ribavirin에 대한 Drug_Interactions 정보
Not Available
|
CYP450
Drug Interaction |
[CYP450 Table직접조회]
|
| Food Interaction |
Bacitracin에 대한 Food Interaction 정보
Not Available
Ribavirin에 대한 Food Interaction 정보
Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Bacitracin에 대한 Description 정보
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.Bacitracin is synthesised via the so-called nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not involved in its synthesis.
Ribavirin에 대한 Description 정보
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]
|
| Dosage Form |
Bacitracin에 대한 Dosage_Form 정보
Ointment TopicalPowder, for solution Intramuscular
Ribavirin에 대한 Dosage_Form 정보
Aerosol Respiratory (inhalation)
|
| Drug Category |
Bacitracin에 대한 Drug_Category 정보
Anti-Bacterial AgentsAnti-Infective Agents, Local
Ribavirin에 대한 Drug_Category 정보
AntimetabolitesAntiviral Agents
|
| Smiles String Canonical |
Bacitracin에 대한 Smiles_String_canonical 정보
CCC(C)C(N)C1=NCC(S1)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NC1CCCCNC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(NC(=O)C(CCCN)NC1=O)C(C)CC
Ribavirin에 대한 Smiles_String_canonical 정보
NC(=O)C1=NN(C=N1)C1OC(CO)C(O)C1O
|
| Smiles String Isomeric |
Bacitracin에 대한 Smiles_String_isomeric 정보
CC[C@@H](C)[C@H](N)C1=NC[C@@H](S1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@H](C)CC
Ribavirin에 대한 Smiles_String_isomeric 정보
NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
|
| InChI Identifier |
Bacitracin에 대한 InChI_Identifier 정보
InChI=1/C66H103N17O16S/c1-9-35(6)52(69)66-72-32-48(100-66)63(97)80-43(26-34(4)5)59(93)75-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)76-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-73-39)77-60(94)44(27-38-18-13-12-14-19-38)81-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)74-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,73)(H,71,89)(H,74,90)(H,75,93)(H,76,98)(H,77,94)(H,78,96)(H,79,95)(H,80,97)(H,81,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36?,37?,40-,41+,42+,43-,44+,45-,46-,47+,48?,52-,53-,54-/m0/s1/f/h71,73-83,85,87H,68H2
Ribavirin에 대한 InChI_Identifier 정보
InChI=1/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1/f/h9H2
|
| Chemical IUPAC Name |
Bacitracin에 대한 Chemical_IUPAC_Name 정보
(4R)-4-[[(2S)-2-[[2-[(1S)-1-amino-2-methylbutyl]4,5-dihydro-1,3-thiazole-5-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-15-butan-2-yl-6-(carboxymethyl)-9-(3H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-12-(phenylmethyl)-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
Ribavirin에 대한 Chemical_IUPAC_Name 정보
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
|
| Drug-Induced Toxicity Related Proteins |
RIBAVIRIN 의 Drug-Induced Toxicity Related Protein정보
Replated Protein:Haptoglobin
Drug:ribavirin
Toxicity:affect hepatic functions.
[바로가기]
Replated Protein:Epidermal growth factor receptor
Drug:ribavirin
Toxicity:affect hepatic functions.
[바로가기]
Replated Protein:Hepatocyte growth factor
Drug:ribavirin
Toxicity:affect hepatic functions.
[바로가기]
|
|
|
| 사용자컨텐츠 |
|
|
|
|
|
-
최근정보수정일 2021-12-09
-
본 수정일 정보는 허가정보 이외의 기타정보 수정일을 의미하므로, 허가정보수정일은 본문에 표기된 날짜를 참조하시기 바랍니다.
|
|
| 알림 |
상세정보는 식품의약품안전처의 제품허가사항을 토대로 작성되었으며 요약정보는 상세정보 및 기타문헌을 기반으로 드럭인포에서 편집한 내용입니다. 제품허가사항의 목차와 다소 상이할 수 있습니다. |
|
| 경고 |
드럭인포 의약학술정보는 식품의약품안전처의 제품허가사항, 학술문헌, 제약회사 제공정보 등을 근거로 작성된 참고 정보입니다.
정보의 정확성을 위해 노력하고 있으나 편집상의 오류, 허가사항 변경, 추가적인 학술연구 또는 임상연구 발표 등으로 인해 발생하는 문제에 대해 드럭인포는
책임을 지지 않습니다. 자세한 내용은 “책임의 한계 및 법적고지”를 참조해 주십시오.
반드시 제조·수입사, 판매사, 의사, 약사에게 최종적으로 확인하시기 바랍니다.
전화: 02-3486-1061 ㅣ 이메일: webmaster@druginfo.co.kr
|
|
아래의 내용을 포함한 전체 데이터를 보시려면
여기로 이동하시기 바랍니다.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ≥4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. RIBAVIRIN[GGT Increase][Composite Activity](Score) I(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGOT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGPT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[LDH Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[GGT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0
병용금기 및 특정연령대 금기 성분
[의약품병용/연령대금기 고시근거로 바로가기] 제목 없음
2008년 8월 1일 약가화일상 8월달 신규등재 및 삭제되는 품목 포함한 병용연령 금기 품목리스트 기준
1. 현재 검색한 제품에 대한 병용금기 제품 존재여부 및 검색
현재 이제품에 대한 병용금기에 해당하는 청구코드별 제품내역 공지내용이 없습니다
2. 연령대금기 존재여부
현재 이제품에 대한 연령금기에 해당하는 청구코드별 공지내용이 없습니다
|
|
|
|
전문/일반
